Disease · MONDO_0018906
Comparisons in its trials154
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 154
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: deaths from any cause | 111 of 692 | 104 of 698 | 1,390 | NCT01332968 | Trial comparisons |
| Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events | 309 of 692 | 361 of 698 | 1,390 | NCT01332968 | Trial comparisons |
| Arm A vs Arm B: Number of Participants With Treatment Emergent Adverse Events (AEs) | 352 of 371 | 347 of 369 | 740 | NCT01724021 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 126 of 371 | 116 of 369 | 740 | NCT01724021 | Trial comparisons |
| Bortezomib + Rituximab vs Rituximab: serious adverse events | 59 of 334 | 37 of 339 | 673 | NCT00312845 | Trial comparisons |
| Bortezomib + Rituximab vs Rituximab: Overall Response Rate | 199 of 315 | 160 of 324 | 639 | NCT00312845 | Trial comparisons |
| GP2013 vs Rituximab: To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths | 29 of 312 | 31 of 315 | 627 | NCT01419665 | Trial comparisons |
| GP2013 vs Rituximab: To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization | 97 of 312 | 78 of 315 | 627 | NCT01419665 | Trial comparisons |
| GP2013 vs Rituximab: To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period | 46 of 311 | 42 of 313 | 624 | NCT01419665 | Trial comparisons |
| GP2013 vs Rituximab: To Evaluate the Partial Response (PR) Rate During the Combination Treatment Period | 225 of 311 | 232 of 313 | 624 | NCT01419665 | Trial comparisons |
| CHOP + Rituximab vs CHOP + Tositumomab: Objective Response (Confirmed and Unconfirmed Complete and Partial Responses) | 224 of 267 | 223 of 265 | 532 | NCT00006721 | Trial comparisons |
| First-line Stratum vs Relapsed/Refractory Stratum: serious adverse events | 35 of 312 | 39 of 177 | 489 | NCT02536664 | Trial comparisons |
| Arm A: Ibrutinib + Rituximab vs Arm B: Placebo + Rituximab: deaths from any cause | 123 of 334 | 40 of 111 | 445 | NCT02947347 | Trial comparisons |
| Arm A: Ibrutinib + Rituximab vs Arm B: Placebo + Rituximab: serious adverse events | 214 of 334 | 48 of 111 | 445 | NCT02947347 | Trial comparisons |
| Bendamustine Alone vs Obinutuzumab + Bendamustine: Number of Participants With PD or Death as Assessed by Investigator | 152 of 209 | 132 of 204 | 413 | NCT01059630 | Trial comparisons |
| Bendamustine Alone vs Obinutuzumab + Bendamustine: Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death | 125 of 209 | 87 of 204 | 413 | NCT01059630 | Trial comparisons |
| Bendamustine Alone vs Obinutuzumab + Bendamustine: serious adverse events | 76 of 203 | 91 of 204 | 407 | NCT01059630 | Trial comparisons |
| Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP): serious adverse events | 76 of 210 | 74 of 197 | 407 | NCT01200758 | Trial comparisons |
| Placebo + Chemoimmunotherapy (CIT) vs Ibrutinib + CIT: deaths from any cause | 61 of 201 | 65 of 202 | 403 | NCT01974440 | Trial comparisons |
| Placebo + Chemoimmunotherapy (CIT) vs Ibrutinib + CIT: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 197 of 199 | 199 of 201 | 400 | NCT01974440 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018906/comparisons